Sorafenib in large hepatocellular carcinoma and advanced liver dysfunction

Background: Patients with multifocal unresectable hepatocellular carcinoma (HCC) have a very poor prognosis, because potential curative treatments are reserved for early stage HCC. Sorafenib is an oral multikinase inhibitor. Encouraging results of a multicentre, placebo-controlled phase III trial using Sorafenib in advanced HCC suggest a survival benefit and good tolerance in Child-Pugh A patients. Here, we evaluated the safety of Sorafenib in patients with unresectable HCC predominantly afflicted with Child-Pugh B or C cirrhosis. Patients and Methods: Between May 2006 and April 2007, 18 patients with advanced H…